01
Why oral gets its own card
People who will not inject still want the molecule. Honesty requires a separate card with the same no.
- ·Gut-target conversations in research
- ·Not a loophole
- ·See injectable BPC-157 for the full evidence layout
RE GEN RX · peptides / BPC-157 (oral)
Needle-free BPC-157 is the same legal file as the injectable — not orderable today.
Oswego, Illinois · 74 W. Washington St · serving the Fox Valley. A licensed Illinois clinician still decides. Compounded medications are not FDA-approved.
Legal status reviewed July 2026 · Needle-free
What is BPC-157 (oral)?
Oral BPC-157 is marketed for gut-lining goals because the parent sequence is gastric. Stomach enzymes destroy most peptides; this molecule is discussed as unusually stable in acid in research settings. None of that creates a 503A pathway. If we cannot compound the bulk substance, we cannot compound the capsule either.
How people usually take it. Not orderable as tablets, capsules, or liquids from RE GEN today.
Interest is not a result. We keep the research language and skip the miracle.
01
People who will not inject still want the molecule. Honesty requires a separate card with the same no.
02
Gastric stability is a chemistry talking point. 503A is a statute talking point. We need the statute.
03
A visit can cover carried tools and referrals. It will not include oral BPC-157 today.
A note on honesty: we will tell you what the literature supports and what it does not. Animal data is not a human guarantee. Anecdotes are not trials.
GI injury and protection models are a large part of the BPC-157 animal literature.
Human oral data are limited. The compounding answer does not change with the route.
Legal basis at RE GEN · July 2026
Same bulk-eligibility status as injectable BPC-157. PCAC recommended listing in July 2026. Not orderable at RE GEN until FDA acts.
PCAC recommended listing is not a green light. Not orderable today.
Peptide education for Illinois patients at RE GEN in Oswego — not a substitute for a visit.
A needle-free form discussed for gut-focused goals. It is not orderable at RE GEN. The bulk substance has no lawful §503A pathway today.
oral BPC-157 is not FDA-approved, and RE GEN does not have a lawful §503A pathway to request it as a compounded medication today. A committee vote is not approval.
You can start a visit to talk about your goal. We will not compound oral BPC-157 today. We will show you what is carried instead — and we will say no rather than gray-market a vial.
Route does not create bulk eligibility. We will not compound oral BPC-157 until the same FDA basis exists as for the injectable.
No. Educational pages explain why people ask and what the research landscape looks like. Individual response varies. Compounded medications are not FDA-approved, and a request is not a guaranteed prescription.
BPC-157 (injectable)
Most-asked repair peptide
Learn more →
TB-500
Often paired with BPC-157
Learn more →
GHK-Cu
Topical solution · 0.25%
Learn more →
KPV
Gut, skin, recovery comfort
Learn more →
Cardiogen
Clinician-matched only
Learn more →
Wolverine Blend
BPC-157 / TB-500
Learn more →
Glow Blend
GHK-Cu / BPC-157 / TB-500
Learn more →
Klow Blend
GHK-Cu / KPV / BPC-157 / TB-500
Learn more →
Illinois practice · licensed 503A compounding
Hello Gorgeous PC · 74 W. Washington St, Oswego, IL
RE GEN desk 630-636-6193
Start a visit, a licensed Illinois clinician reviews, then you pay the invoice. If they don't prescribe, we refund.